MigVax’s Subunit Oral COVID-19 Vaccine Preclinical Trial Demonstrates Effectivity as a Booster

MigVax Ltd., a startup company developing an oral subunit vaccine against COVID-19, today announced promising results from preclinical tests that demonstrated the effectivity of its MigVax-101 subunit oral vaccine as a booster for previously vaccinated persons.